Jose Gutierrez‐Fernandez

The objectives of this study were to perform a systematic review of publications between 2010 and 2021 on the antibiotic resistance of Pseudomonas aeruginosa and Acinetobacter baumannii from urinary tract infections and to analyze changes over time in hospital urine cultures from 2016 through 2021. The literature was searched, and a retrospective cross‐sectional descriptive study was performed in the hospital. Out of 21 838 positive urine cultures, 3.86% were due to P. aeruginosa and 0.44% were due to A. baumannii . For P. aeruginosa , lower resistance rates were observed to virtually all tested antibiotics than were obtained in the systematic review, and the present series of hospital samples showed an in vitro resistance rate <10% to ceftazidime, cefepime, meropenem, piperacillin‐tazobactam, amikacin, tobramycin, and colistin. For A. baumannii , the resistance rates to almost all antibiotics were higher in the present series than in the systematic review, being lowest to colistin (10%). Both microorganisms show reduced in vitro susceptibility to some antibiotics during the years of the COVID‐19 pandemic in comparison to previous years. In our setting, both piperacillin‐tazobactam and meropenem can be recommended for the empirical treatment of UTIs by P. aeruginosa , whereas only colistin can be recommended for UTIs by A. baumannii .